Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-04-23
DOI
10.1093/annonc/mdz134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
- (2019) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
- (2018) James X. Sun et al. PLoS Computational Biology
- Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
- (2017) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies
- (2017) Ryan J. Hartmaier et al. Genome Medicine
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
- (2016) Zsofia K. Stadler et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- OptiType: precision HLA typing from next-generation sequencing data
- (2014) András Szolek et al. BIOINFORMATICS
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started